Injector pen

TempraMed's VIVI Cap 1 is changing the way people who inject insulin live their lives

Retrieved on: 
Friday, July 16, 2021
Clinical medicine, Branches of biology, Organ systems, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Injector pen, Insulin pump, Insulin aspart

TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.

Key Points: 
  • TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.
  • From the point of manufacturing up until it is used, insulin needs to be kept between 36 to 46F.
  • During use, insulin does not have to be refrigerated but it should stay below 86F and should not freeze.
  • Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Global Insulin Pens Market 2021-2025: Increasing Product Launches & Growing Prevalence of Diabetes Cases - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Pharmaceutical, Health, Medical devices, Clinical medicine, Organ systems, Branches of biology, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Injector pen, Market analysis

The insulin pens market is poised to grow by $3.43 billion during 2021-2025, progressing at a CAGR of about 8%

Key Points: 
  • The insulin pens market is poised to grow by $3.43 billion during 2021-2025, progressing at a CAGR of about 8%
    The report on the insulin pens market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by the growing prevalence of diabetes cases and rising government initiatives to prevent diabetes in developed countries.
  • This study identifies the increasing product launches as one of the prime reasons driving the insulin pens market growth during the next few years.
  • Also, the insulin pens market analysis report includes information on upcoming trends and challenges that will influence market growth.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Glooko, Injector pen, Diabetes management software, Intensive insulin therapy

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Medicine, Organ systems, Diabetes, Insulin, Carbohydrate counting, Blood glucose monitoring, Type 1 diabetes, Injector pen, Intensive insulin therapy, Insulin pump

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Diabetes, Organ systems, Medicine, Diabetes management, Insulin, Type 2 diabetes, Type 1 diabetes, Hypoglycemia, Injector pen, Intensive insulin therapy, Book:Diabetes mellitus type 1

"Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.

Key Points: 
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • These solutions may also help address psychological barriers like fear of hypoglycemia that may negatively impact diabetes management.
  • Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases2.
  • These agreements and the Tempo Pen and Tempo Smart Button are part of Lilly\'s current and contemplated connected diabetes solutions and reflect Lilly\'s current beliefs and expectations.

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Medicine, Organ systems, Diabetes, Insulin, Carbohydrate counting, Blood glucose monitoring, Type 1 diabetes, Injector pen, Intensive insulin therapy, Insulin pump

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Glooko, Injector pen, Diabetes management software, Intensive insulin therapy

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes

Retrieved on: 
Tuesday, April 13, 2021
Research, Medical devices, FDA, Diabetes, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Clinical medicine, Medicine, Endocrine system, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Injector pen, Intensive insulin therapy, Diabetes management

Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2.

Key Points: 
  • Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2.
  • We are really proud to be leading it with Roche Diabetes Care France.
  • We are committed to the autonomy and quality of life of patients with diabetes, empowering them to understand and act on their condition.
  • This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes.

The Fast Way to a Safe Insulin Pen

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Branches of biology, Peptide hormones, Recombinant proteins, Insulin, Diabetes, Injector pen

"We have installed more than 100 servo press kits in the automated assembly lines for insulin pens," said Ulrik Keldke, Head of Syntegon's engineering department.

Key Points: 
  • "We have installed more than 100 servo press kits in the automated assembly lines for insulin pens," said Ulrik Keldke, Head of Syntegon's engineering department.
  • "Automating the assembly line is a prerequisite for meeting the requirements for the end product: the insulin pens must be safe and user-friendly," said Andersen.
  • "The automated systems ensure that the insulin pens are always in order and can deliver the exact amount of insulin."
  • The assembly line for insulin pens can be expanded into a complete line with other systems from the company.

BIOCORP Signs Two New Partnerships With Mallya Technology

Retrieved on: 
Wednesday, February 17, 2021
Other Health, Software, Managed care, General Health, Data management, Medical devices, Technology, Hospitals, Fitness & Nutrition, Biotechnology, Health, Diabetes, Injector pen, Medical equipment, Mallya, Medicine, Insulin, Clinical medicine, Pharmacology

These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.

Key Points: 
  • These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
  • ric Dessertenne, CEO of BIOCORP, explained: These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market.
  • Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers.
  • Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.